The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Share Consolidation & Admission Warrants

2 Jun 2021 09:32

RNS Number : 5579A
Motif Bio PLC
02 June 2021
 

 

2 June 2021

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN MOTIF BIO PLC OR ANY OTHER ENTITY IN ANY JURISDICTION.

 

 

Motif Bio plc

("Motif" or the "Company")

 

Update on Share Consolidation and Admission Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, provides an update on the Share Consolidation and Admission Warrants that were detailed in its announcement of 26 May 2021.

 

The Company's current issued share capital of 654,991,023 will be adjusted through a proposed Share Consolidation to 2,977,231 New Ordinary Shares. The Company will issue 27,502,645 Consideration Shares for the proposed acquisition of BiVictriX (the "Acquisition"). On a primary basis, prior to the concurrent £10.1 million Fundraising, the Company will have 30,479,876 New Ordinary shares outstanding and issued.

 

As additional consideration, Admission Warrants over 1,488,615 New Ordinary Shares are to be issued for the benefit of existing Motif shareholders.  

 

The Admission Warrants will be granted on the basis of one Admission Warrant per two New Ordinary Shares held immediately prior to completion of the Acquisition, with an exercise price of 30 pence and valid for 180 days following Admission which is expected to be on or around 8.00 a.m. on 15 June 2021.

 

The Admission Warrants will not be listed or admitted to trading, are not freely transferable and will be issued to existing Motif shareholders in certificated form by 25 June 2021.

 

The Acquisition details, as provided above, are all conditional on Shareholder support of all Resolutions at the General Meeting. For additional information on the Acquisition, please see the Admission Document which is posted on the Company's website (www.motifbio.com).

 

As all Resolutions to be voted on at the General Meeting are conditional, all Resolutions must be approved by shareholders for the Acquisition to proceed. Motif Bio plc will not be able to continue operations in the absence of this Acquisition. As a result, if all Resolutions are not approved by shareholders, it is expected that Motif's shares would be de-listed from the AIM market and Shareholders would receive no further value.

 

 

Expected Timetable of Principal Events

 

 Time and date of the General Meeting

12.00 p.m. on 14 June 2021

Announcement of the result of the General Meeting

14 June 2021

Record date for the issue of the Admission Warrants

6.00 p.m. on 14 June

Ex-date of the issue of the Admission Warrants

15 June 2021

Despatch of Admission Warrant certificates

By 25 June 2021

 

 

The Admission Document and further information on the Company can be found on Motif's website at: www.motifbio.com

Capitalised terms used in this announcement carry the same meanings as those ascribed to them in the Company's Admission Document dated 26 May 2021 and/or the Company's announcement of 26 May 2021, unless the context requires otherwise.

For further information please contact:

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (Non-Executive Director)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0) 20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Rob Rees (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0) 20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

 

 

Forward-Looking Statements

This announcement may contain forward-looking statements. Words such as "expects", "anticipates", "may", "should", "would", "could", "will", "intends", "plans", "believes", "targets", "seeks", "estimates", "aims", "projects", "pipeline" and variations of such words and similar expressions are intended to identify such forward-looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate transactions and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence and changes in the legal or regulatory environment.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSSSSAEEFSEEM
Date   Source Headline
8th Jun 20172:32 pmRNSHolding(s) in Company
5th Jun 20176:20 pmRNSPublication of Shareholder Circular
2nd Jun 20174:36 pmRNSResult of Placing
2nd Jun 20177:00 amRNSProposed Placing
23rd May 20174:40 pmRNSSecond Price Monitoring Extn
23rd May 20174:35 pmRNSPrice Monitoring Extension
18th May 20177:00 amRNSPublication of UK Annual Report and Accounts
10th May 20177:00 amRNSAppointments to Scientific Advisory Board
5th May 20177:00 amRNSDirectorate Change
2nd May 20173:10 pmRNSExercise of Warrants and Issue of Equity
2nd May 20177:00 amRNSAnnual Financial Report
28th Apr 201712:00 pmRNSChange of Adviser
24th Apr 20177:00 amRNSNotification of change in holding of shareholder
18th Apr 20177:00 amRNSPositive Data Readout for Iclaprim Phase 3 Trial
12th Apr 20173:06 pmRNSHolding(s) in Company
12th Apr 20173:01 pmRNSHolding(s) in Company
31st Mar 20174:15 pmRNSChange of Registered Office
8th Feb 20172:57 pmRNSInvestor Presentation
8th Feb 20177:00 amRNSDirector/PDMR Shareholding
7th Feb 20177:02 amRNSDirector/PDMR Shareholding
31st Jan 20173:36 pmRNSHardman Research: Further de-risking of iclaprim
31st Jan 20177:00 amRNSClinical trial finishes patient treatment phase
27th Jan 20176:13 pmRNSHolding(s) in Company
18th Jan 20177:05 amRNSDirector/PDMR Shareholding
18th Jan 20177:00 amRNSAppointment of Chief Financial Officer
9th Jan 20175:28 pmRNSIssue of Equity
3rd Jan 201712:31 pmRNSHolding(s) in Company
30th Dec 20163:09 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
21st Dec 20165:50 pmRNSConversion of CPNs, PDMR Dealing & TVR
21st Dec 20164:17 pmRNSIssue of Equity & Total Voting Rights
21st Dec 20163:05 pmRNSResult of GM
19th Dec 20165:58 pmRNSHolding(s) in Company
8th Dec 20167:45 amRNSHolding(s) in Company
5th Dec 20167:00 amRNSPublication of circular and notice of GM
1st Dec 20165:27 pmRNSIssue of Equity
25th Nov 201611:32 amRNSHolding(s) in Company
24th Nov 20161:36 pmRNSHolding(s) in Company
23rd Nov 20165:12 pmRNSHolding(s) in Company
23rd Nov 20164:56 pmRNSClosing of public offer
18th Nov 201612:51 pmRNSConfirms successful European placing
18th Nov 20167:16 amRNSUS Pricing and European Placing to raise US$25m
4th Nov 20161:34 pmRNSHolding(s) in Company
4th Nov 20161:20 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSUpdate on US Public Offering
31st Oct 20167:00 amRNSNew Data on Iclaprim
31st Oct 20167:00 amRNSData Confirming Standard Clinical Trial Dosage
16th Sep 20164:40 pmRNSSecond Price Monitoring Extn
16th Sep 20164:35 pmRNSPrice Monitoring Extension
15th Sep 20167:00 amRNSPosters presented at IDWeek New Orleans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.